Retrospective Cohort Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 6, 2021; 9(1): 47-60
Published online Jan 6, 2021. doi: 10.12998/wjcc.v9.i1.47
Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension
Ci Tian, Nan Li, Yi Bai, Han Xiao, Shu Li, Qing-Gang Ge, Ning Shen, Qing-Bian Ma
Ci Tian, Yi Bai, Shu Li, Qing-Bian Ma, Department of Emergency Medicine, Peking University Third Hospital, Beijing 100191, China
Nan Li, Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China
Han Xiao, Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing 100191, China
Qing-Gang Ge, Department of Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China
Ning Shen, Department of Pulmonary and Critical Care Medicine, Department of Medicine, Peking University Third Hospital, Beijing 100191, China
Author contributions: Tian C conceived and designed the study; Tian C and Bai Y collected the data of this study; Li N performed the data analysis; Tian C wrote the manuscript; Li S reviewed and edited the manuscript; Ma QB designed research; all authors read and approved the manuscript. Tian C, Li N and Bai Y contributed equally to the manuscript.
Institutional review board statement: This study was approved by Institutional Review Board of Peking University Third Hospital, China (No. IRB00006761-M2020060).
Informed consent statement: The study was approved by Institutional Review Board of Peking University Third Hospital and got waiver of written informed consent.
Conflict-of-interest statement: The authors declare that there is no conflict of interest.
Data sharing statement: The data used to support the findings of this study are available from the corresponding author upon request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qing-Bian Ma, MD, Associate Professor, Chairman, Chief Physician, Department of Emergency Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China. maqingbian@bjmu.edu.cn
Received: October 9, 2020
Peer-review started: October 9, 2020
First decision: November 3, 2020
Revised: November 9, 2020
Accepted: November 21, 2020
Article in press: November 21, 2020
Published online: January 6, 2021
Processing time: 84 Days and 3.3 Hours
Core Tip

Core Tip: Recent research revealed that use of angiotensin converting enzymes inhibitors or angiotensin receptor blockers (ACEIs/ARBs) had no significant harm on coronavirus disease 2019 (COVID-19) patients complicated with hypertension. However, the impact of discontinue using ACEIs/ARBs in those patients was still unclear. In the present study, we retrospectively collected the clinical data of patients with both COVID-19 and hypertension to explore whether any difference in disease outcomes existed between patients who discontinued using ACEIs/ARBs and those who continued using other anti-hypertensive drugs.